SCHEMBL5096009

SCHEMBL5096009

Nc1cc(N)n2ncnc2n1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGLN2 Q96KS0 3/20 0.50
ALDH1A1 P00352 4/20 0.46
NPSR1 Q6W5P4 1/20 0.41
ENPP1 P22413 3/20 0.41
KDM4E B2RXH2 5/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAPK1 P28482 2/20 0.38
TSHR P16473 2/20 0.38
PKM P14618 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPT P10636 1/20 0.38
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.38
ATM Q13315 1/20 0.37
GAA P10253 1/20 0.36
HTT P42858 1/20 0.36
MBOAT4 Q96T53 2/20 0.35
DYRK1A Q13627 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL609785 0.80 ALDH1A1 (0.67) ALDH1A1NPSR1ENPP1KDM4ESMN1; SMN2
SCHEMBL10887539 0.80 ALDH1A1 (0.43) EGLN2ALDH1A1NPSR1ENPP1KDM4E
SCHEMBL4425907 0.77 ALDH1A1 (0.44) ALDH1A1KDM4ESMN1; SMN2HPGDGAA
SCHEMBL609545 0.76 KDM1A (0.44) ALDH1A1NPSR1ENPP1SMN1; SMN2MAPK1
Hydrochloric Acid SCHEMBL31728199 0.74 UBE2M (0.43) EGLN2ALDH1A1NPSR1ENPP1KDM4E
SCHEMBL3636753 0.71 ALDH1A1 (0.42) EGLN2ALDH1A1ENPP1KDM4ESMN1; SMN2
SCHEMBL5420423 0.70 ALDH1A1 (0.44) EGLN2ALDH1A1NPSR1ENPP1KDM4E
SCHEMBL15063412 0.69 GAA (0.47) ALDH1A1NPSR1SMN1; SMN2MAPK1TSHR
SCHEMBL1650004 0.68 ALDH1A1 (0.49) EGLN2ALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL18077064 0.68 EGLN2 (1.00) EGLN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1618108-A2 TRIAZOLO[1,5-A]PYRIMIDINES AND PYRAZOLO[1,5-A]PYRIMIDINES USEFUL AS A2A ADENOSINE RECEPTOR ANTAGONISTS Biogen Idec MA Inc. (US) 2006-01-25 EP claimed
WO-2004092171-A2 TRIAZOLO[1,5-A]PYRIMIDINES AND PYRAZOLO[1,5-A]PYRIMIDINES USEFUL AS A2A ADENOSIN E RECEPTOR ANTAGONISTS BIOGEN IDEC MA INC. (US) 2004-10-28 WO claimed
WO-2022189189-A1 TRICYCLIC PESTICIDAL COMPOUNDS BASF SE (DE) 2022-09-15 WO disclosed
US-20080070932-A1 Triazolo[ 1,5-A] Pyrimidines And Pyrazolo[ 1,5-A] Pyrimidines And Methods Of Making And Using The Same BIOGEN IDEC MA INC. 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070932-A1 Triazolo[ 1,5-A] Pyrimidines And Pyrazolo[ 1,5-A] Pyrimidines And Methods Of Making And Using The Same ADORA2B, ADORA2A, ADORA1 EGLN2 4225/4885ALDH1A1 279/4885NPSR1 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.